anidulafungin
Phase 2Terminated 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ventilator Associated Pneumonia
Conditions
Ventilator Associated Pneumonia, Respiratory Tract Infection
Trial Timeline
Apr 1, 2010 → Aug 1, 2012
NCT ID
NCT00934934About anidulafungin
anidulafungin is a phase 2 stage product being developed by Pfizer for Ventilator Associated Pneumonia. The current trial status is terminated. This product is registered under clinical trial identifier NCT00934934. Target conditions include Ventilator Associated Pneumonia, Respiratory Tract Infection.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01202253 | Pre-clinical | Completed |
| NCT00934934 | Phase 2 | Terminated |
| NCT01053884 | Phase 2 | Terminated |
| NCT00537329 | Phase 3 | Completed |
| NCT00056381 | Phase 1/2 | Completed |
Competing Products
9 competing products in Ventilator Associated Pneumonia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Doripenem + Imipenem-Cilastatin + Placebo | Johnson & Johnson | Phase 3 | 77 |
| Imipenem/cilastatin + Imipenem/cilastatin + Doripenem + Doripenem | Johnson & Johnson | Phase 2 | 52 |
| Ceftolozane/Tazobactam + Piperacillin/Tazobactam | Merck | Phase 3 | 77 |
| Imipenem + Imipenem | Merck | Approved | 85 |
| Vancomycin + Linezolid | Pfizer | Approved | 84 |
| Linezolid | Pfizer | Pre-clinical | 22 |
| aerosolized vancomycin or gentamicin | Nektar Therapeutics | Phase 2 | 47 |
| IC43 + Placebo | Valneva SE | Phase 2 | 47 |
| Ceftobiprole | Basilea Pharmaceutica | Phase 1 | 28 |